Medtronic Announces Long-Term Data From Its SPYRAL HTN-ON MED Clinical Trial That Showed Subjects Who Underwent Radiofrequency Renal Denervation With The Symplicity Spyral Renal Denervation System Had Greater Reductions In 24-Hr ABPM, And OSBP...
Medtronic Announces Long-Term Data From Its SPYRAL HTN-ON MED Clinical Trial That Showed Subjects Who Underwent Radiofrequency Renal Denervation With The Symplicity Spyral Renal Denervation System Had Greater Reductions In 24-Hr ABPM, And OSBP...
Medtronic Announces Long-Term Data From Its SPYRAL HTN-ON MED Clinical Trial That Showed Subjects Who Underwent Radiofrequency Renal Denervation With The Symplicity Spyral Renal Denervation System Had Greater Reductions In 24-Hr ABPM, And OSBP Compared To Sham Patients At 2-Years
美敦力宣佈其SPYRAL HTN-ON MED臨床試驗的長期數據顯示，在接受Symplicity Spyral腎臟射頻消融系統射頻腎臟消融的受試者在2年內比安慰組患者在24小時動態動脈血壓監測和辦公室收縮壓方面有更大的降低。
Company commits to advancing clinical data for Symplicity with the SPYRAL Gemini clinical trial and expansion of the GSR-DEFINE clinical trial
公司致力於推動Symplicity的臨床數據，通過SPYRAL Gemini臨床試驗以及GSR-DEFINE臨床試驗的擴大。
GALWAY, Ireland and WASHINGTON, Oct. 28, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced new, long-term data from its SPYRAL HTN-ON MED clinical trial that showed subjects who underwent radiofrequency renal denervation with the Symplicity Spyral renal denervation (RDN) system had significantly greater reductions in 24-hr ambulatory systolic blood pressure (ABPM), and office-based systolic blood pressure (OSBP) compared to sham patients at two years. The data were presented as a part of the 2024 Transcatheter Cardiovascular Therapeutics Conference (TCT).
愛爾蘭戈爾韋和華盛頓，2024年10月28日 / PRNewswire / - 全球衛生保健科技領導者美敦力plc（NYSE：MDT）今天宣佈了來自其SPYRAL HTN-ON MED臨床試驗的新的長期數據，顯示接受Symplicity Spyral腎臟消融（RDN）系統射頻腎臟消融的受試者在兩年內24小時動態收縮血壓（ABPM）和辦公室收縮血壓（OSBP）方面的降壓明顯大於安慰組患者。這些數據作爲2024年經皮血管介入心臟治療學會議（TCT）的一部分進行了介紹。
譯文內容由第三人軟體翻譯。
